Dec. 20 Company Quick Takes: Genmab partners with CureVac; plus pair of Biogen deals, Ionis, Akcea-Novartis, Paratek and J&J-Taris
CureVac, Genmab to develop RNA-encoded antibody
Genmab A/S (NASDAQ:GMAB; CSE:GMAB) and CureVac AG have partnered to discover an mRNA-encoded antibody candidate to treat cancer. Genmab will pay $10 million up front and invest €20 million ($22.2 million) in CureVac. Genmab has an option to license three additional programs within five years. CureVac is eligible for $275-$368 million in milestones per product, plus undisclosed royalties (see “The Quiet Disrupters: DNA-encoded and RNA-encoded Antibodies”).
Biogen in deals with Catalyst, Ionis
In a pair of deals, Biogen Inc. (NASDAQ:BIIB) gained exclusive global rights for pegylated CB 2782 (CB 2782-PEG) and other anti-C3 proteases from Catalyst Biosciences Inc. (NASDAQ:CBIO); and licensed BIIB080 (IONIS-MAPTRx) from Ionis Pharmaceuticals Inc. (NASDAQ:IONS)...